J.P. Morgan Notebook, Jan. 14: AbbVie, AstraZeneca, Juno & Bluebird
This article was originally published in The Pink Sheet Daily
Day three of “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing remains center stage, with AbbVie weighing in on HCV and AstraZeneca’s Soriot predicting cost-competition in oncology. CAR-T continues to advance, with updates from Juno and bluebird.
You may also be interested in...
Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing talk dominates day two, and companies weigh in on the fallout from failed M&A.
AstraZeneca has an ambitious agenda to become a leader in oncology. The company’s notably improved pipeline is broad, but winning will require AstraZeneca to come from behind to uncover the best combinations ahead of the competition.